TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15246631
Drug: HPV11 L1
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV11 L1 VLP vaccine (50 microg)
Study: 15246631
Drug: HPV11 L1
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV11 L1 VLP vaccine (100 microg)
Study: 15246631
Drug: HPV16 L1
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16 L1 VLP vaccine (10 microg)
Study: 15246631
Drug: HPV16 L1
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16 L1 VLP vaccine (40 microg)
Study: 15246631
Drug: HPV16 L1
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16 L1 VLP vaccine (80 microg)
Study: 9304946
Drug: Enteroclysis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteroclysis therapy
Study: 8392360
Drug: Terbutaline 7.5
Normalized name: terbutaline 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 7.5 mg, administered twice daily for 1 week
Study: 8392360
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg, administered twice daily for 1 week
Study: 3511328
Drug: Bubble oxygenator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bubble oxygenator with methylprednisolone sodium succinate (30 mg/kg)
Study: 3763651
Drug: Flupenthixol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol (0.5 mg for the first week, then doubled for 3 weeks)
Study: 3763651
Drug: Diazepam (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (2.5 mg for the first week, then doubled for 3 weeks)
Study: 24565296
Drug: Propofol via
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol via patient‐controlled analgesia device (400 μg.kg(‐1), 5‐minute lockout interval, no basal infusion)
Study: 24565296
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion using the same settings as Group P
Study: 19004308
Drug: Low Intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Intensity Laser Therapy (LILT) - Infrared laser (780 nm, 70 mw, 60s, 105J/cm2), applied twice per week for a total of eight sessions
Study: 10723834
Drug: Post-treatment self-efficacy
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment self-efficacy
Study: 1532198
Drug: Cl2MDP (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cl2MDP (300 mg IV for 7 days, then 200 mg IM for 14 days)
Study: 1532198
Drug: Cl2MDP (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cl2MDP (1,200 mg/d orally) plus chemotherapy (group B)
Study: 1532198
Drug: Cl2MDP treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cl2MDP treatment in osteoblastic metastases
Study: 18617099
Drug: Mini-implants as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-implants as anchor units (G1)
Study: 11876261
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol esters (PSE) at a dosage of 3.6 g/d in salad dressings (ranch or Italian) for 3 weeks
Study: 9918342
Drug: Tolcapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone (200 mg three times daily)
Study: 9918342
Drug: Bromocriptine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (titrated from 1.25 mg once daily to a mean final dose of 22.4 mg/day)
Study: 7554756
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion (15 micrograms min‐1 kg‐1)
Study: 6101676
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of intravaginal purified porcine relaxin
Study: 31200830
Drug: Cisplatin added
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin added to single-agent chemotherapy
Study: 31200830
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent chemotherapy without cisplatin
Study: 25802471
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + GIMM (GI microbiome modulator)
Study: 23981773
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 5,000 IU daily
Study: 23981773
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 10,000 IU daily
Study: 17157654
Drug: Acetone‐precipitated extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetone‐precipitated extract containing 0.6 mug Can f 1 per 0.5 mL maintenance dose
Study: 17157654
Drug: Acetone‐precipitated extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetone‐precipitated extract containing 3.0 mug Can f 1 per 0.5 mL maintenance dose
Study: 17157654
Drug: Acetone‐precipitated extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetone‐precipitated extract containing 15.0 mug Can f 1 per 0.5 mL maintenance dose
Study: 14511168
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (n=10)
Study: 10575661
Drug: GLN-antioxidants (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLN-antioxidants (40 g/d)
Study: 10575661
Drug: Control (glycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (glycine 40 g/d)
Study: 8701786
Drug: Mestranol plus
Normalized name: Mestranol
DrugBank: Mestranol (DB01357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mestranol plus paramethasone (80 micrograms + 6 mg/day for 10 days)
Study: 6224685
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg norfloxacin twice daily for ten days
Study: 6224685
Drug: 480 mg
Normalized name: magaldrate 480 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg cotrimoxazole twice daily for ten days
Study: 30417614
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g TXA IV + 1 g TXA IA
Study: 30417614
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g TXA IV + 2 g TXA IA
Study: 30417614
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g TXA IV + 3 g TXA IA
Study: 18789826
Drug: Late wake
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late wake therapy (LWT) (sleep 21:00-01:00 h)
Study: 18789826
Drug: Early wake
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early wake therapy (EWT) (sleep 03:00-07:00 h)
Study: 15655136
Drug: Eprosartan (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (600 mg OD)
Study: 12847817
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor-based triple therapies
Study: 12847817
Drug: H2-blockers based
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-blockers based triple combinations lasting 10-14 days
Study: 12847817
Drug: Classical triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical triple therapy (bismuth + 2 antimicrobials)
Study: 12847817
Drug: Clarithromycin-based therapies
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin-based therapies
Study: 12847817
Drug: Nitroimidazoles-based therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroimidazoles-based therapies
Study: 12847817
Drug: Amoxicillin-based therapies
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin-based therapies
Study: 12847817
Drug: Doxycyclin-based therapies
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycyclin-based therapies
Study: 31034254
Drug: High-dose KS
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose KS drinks
Study: 26555862
Drug: Adant® (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adant® (sodium hyaluronate injection)
Study: 26555862
Drug: Artz® (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artz® (sodium hyaluronate injection)
Study: 9031875
Drug: DTaP (diphtheria
Normalized name: Daptacel DTaP (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP (diphtheria and tetanus toxoid acellular pertussis vaccine)
Study: 9031875
Drug: DTwP (diphtheria
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP (diphtheria and tetanus toxoid whole-cell pertussis vaccine)
Study: 30776134
Drug: JNJ-61178104 (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-61178104 (0.1, 0.3, 1, 3, and 10 mg/kg IV; 1 mg/kg SC)
Study: 30776134
Drug: JNJ-61178104 (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-61178104 (IV administration)
Study: 30776134
Drug: JNJ-61178104 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-61178104 (1 mg/kg SC)
Study: 30776134
Drug: JNJ-61178104 (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-61178104 (active treatment)
Study: 29149379
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (IT plus systemic)
Study: 27386647
Drug: Tanshinone IIA
Normalized name: autoprothrombin IIA
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanshinone IIA (T II A) at 80 mg/day for 3 successive days before oxaliplatin chemotherapy
Study: 22298793
Drug: SLE with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLE with Therapy (480 patients)
Study: 22298793
Drug: SLE No
Normalized name: AVOBENZONE 30 mg in 1 g / OCTISALATE 50 mg in 1 g / OCTOCRYLENE 80 mg in 1 g TOPICAL AEROSOL, SPRAY [Cay Skin Isle Nourishing Body Mist SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLE No Therapy (75 patients)
Study: 22298793
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) monotherapy (105 patients)
Study: 22298793
Drug: Prednisone (PRED)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (PRED) ≥20 mg (76 patients)
Study: 22298793
Drug: PRED ≥20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRED ≥20 mg + IS
Study: 22298793
Drug: PRED ≥20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRED ≥20 mg + CQ
Study: 22298793
Drug: PRED ≥20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRED ≥20 mg + IS + CQ
Study: 18024208
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy (supervised training for 10 weeks)
Study: 15005875
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg, four times a day)
Study: 9425399
Drug: Octreotide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (300 micrograms daily for 1 month)
Study: 8214737
Drug: Flumazenil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.1 mg/kg) followed by placebo (NaCl 0.9%)
Study: 8214737
Drug: Flumazenil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.1 mg/kg) followed by midazolam (0.1 mg/kg)
Study: 8214737
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by midazolam (0.1 mg/kg)
Study: 30821897
Drug: Synbiotic supplement
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplement (100 mg Lactobacillus coagulans and fructo‐oligosaccharides, 2 tablets per day for 8 weeks)
Study: 24620666
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise therapy (40-60 minutes a day, 3-4 days a week)
Study: 15731536
Drug: Intravenous nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicorandil (Group II)
Study: 15731536
Drug: Intravenous isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isosorbide dinitrate (Group I)
Study: 7659475
Drug: Whole-cell vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell vaccine (WCL)
Study: 2485347
Drug: Modified formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified formula of parenteral nutrition
Study: 2485347
Drug: Standard formula
Normalized name: Standard formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formula of parenteral nutrition
Study: 1173763
Drug: Iron preparation
Normalized name: IRON PREPARATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron preparation SA (Eryfer)
Study: 1173763
Drug: Iron preparation
Normalized name: IRON PREPARATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron preparation SC (effervescent tablet)
Study: 1173763
Drug: Iron preparation
Normalized name: IRON PREPARATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron preparation SD (sustained release)
Study: 1173763
Drug: Iron preparation
Normalized name: IRON PREPARATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron preparation SE (enteric-coated pellets)
Study: 27984823
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) 25 mg 1 qd for maximal 7 days
Study: 16616167
Drug: Barriers to
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barriers to Treatment Inventory (BTI) administered to substance abusers
Study: 11890592
Drug: Naloxone low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone low dose (LD) - bolus 27 microg/kg; continuous 50 microg/kg/hr
Study: 11890592
Drug: Naloxone high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone high dose (HD) - bolus 54.5 microg/kg; continuous 100 microg/kg/hr
Study: 9399710
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment strategies
Study: 7699476
Drug: GCNS monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GCNS monitoring with daily patient visits
Study: 3109663
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg initially, followed by 4 mg every six hours)
Study: 31724348
Drug: Estazolam (medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam (medication group)
Study: 23707115
Drug: AMPAR peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMPAR peptide assay (0.05-0.40 ng/mL for controls, 1.0-8.5 ng/mL for concussions)
Study: 23707115
Drug: AMPAR peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMPAR peptide values in athletes with multiple concussions (2.0-12.0 ng/mL)
Study: 15208586
Drug: Inhaled fluticasone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone, 500 microg twice daily for 14 days
Study: 9636522
Drug: MMF 1
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 1 g
Study: 9636522
Drug: MMF 2
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 2 g (mean dose adjusted to 1.5 g by 6 months)
Study: 8160943
Drug: Fentanyl (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (same dose) plus clonidine 4 micrograms.kg-1 in 20 min + 2 micrograms.kg-1.h-1 (group B)
Study: 8160943
Drug: Fentanyl plus
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl plus clonidine (same dosage) plus lignocaine 2 mg.kg-1 before skin incision, repeated before peritoneal incision and retractor placement (group C)
Study: 8160943
Drug: Fentanyl plus
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl plus clonidine (same dosage) plus lignocaine 2 mg.kg-1 before skin incision, repeated before peritoneal incision and retractor placement (group D)
Study: 31077432
Drug: PK-guided dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK-guided dosing of paclitaxel
Study: 31077432
Drug: BSA-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSA-based dosing of paclitaxel
Study: 28259326
Drug: Low-dose screening
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose screening chest CT
Study: 23850386
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied on the contralateral thigh
Study: 21346159
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose remifentanil (0.2 μg · kg(‐1) · min(‐1))
Study: 21346159
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose remifentanil (0.4 μg · kg(‐1) · min(‐1))
Study: 18432177
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (DES) with antiproliferative drugs attached via polymers
Study: 8666176
Drug: Dobutamine echocardiography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine echocardiography (TED) with incremental dobutamine infusion: 5 to 40 ncg/kg/min, continued with atropine 0.25 to 1 mg iv if necessary
Study: 8666176
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TED and TE results
Study: 1632167
Drug: Glycopyrrolate (0.003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (0.003 and 0.0075 mg/kg)
Study: 1632167
Drug: Atropine (0.006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.006 and 0.015 mg/kg)
Study: 25980345
Drug: Adjunctive raloxifene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive raloxifene treatment (120 mg per day)
Study: 22289524
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with docetaxel, cisplatin and 5-fluorouracil/leucovorin (NCT group)
Study: 22289524
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy alone (non-NCT group)
Study: 15228463
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide IV
Study: 15228463
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg metoclopramide IV (up to 32 mg)
Study: 11390121
Drug: Aerodiol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerodiol 300 microg, once daily
Study: 2890156
Drug: Psychoactive agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoactive agents
Study: 26210542
Drug: NOCTP: non-operative
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOCTP: non-operative caries treatment programme
Study: 16942960
Drug: Mental reinstatement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental reinstatement of the treatment context before follow-up test
Study: 16942960
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy in one of two contexts
Study: 12940592
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (GK501) 120 mg
Study: 9249121
Drug: Ketoprofen (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (1.5 mg/kg) + Morphine (0.1 mg/kg)
Study: 9249121
Drug: Ketoprofen (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (1.5 mg/kg)
Study: 8322695
Drug: Diltiazem (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120 mg orally)
Study: 8322695
Drug: Nitroglycerin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (0.5 mg sublingually)
Study: 3011329
Drug: Enalapril (10‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10‐40 mg/day, p.o., for 6 weeks)
Study: 3011329
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg/day, p.o.) alone for 2 weeks
Study: 3011329
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg/day, p.o.) in combination with propranolol (80‐160 mg/day, p.o.) for 4 weeks
Study: 26587088
Drug: Standard methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard methods to determine medication dosing (control)
Study: 20638190
Drug: PENTOCLO (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: PENTOCLO (800 mg pentoxifylline, 1,000 IU vitamin E, and 1,600 mg clodronate 5 days per week alternating with 20 mg prednisone and 1,000 mg ciprofloxacin 2 days per week)
Study: 15324522
Drug: fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibrate 200 mg + ezetimibe 10 mg
Study: 15324522
Drug: fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibrate 200 mg
Study: 10926898
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine extract (1 g/day, equivalent to 375 mL of red wine)
Study: 10926898
Drug: Quercetin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (30 mg/day)
Study: 8359587
Drug: Recombinant insulin-like
Normalized name: Recombinant human insulin-like growth factor 1
DrugBank: Recombinant human insulin-like growth factor 1 (DB18684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant insulin-like growth factor I (40 micrograms/kg body weight)
Study: 3024866
Drug: Loperamide (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (16 mg orally)
Study: 3024866
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose naloxone infusion (180 min after loperamide administration)
Study: 24937541
Drug: Pioglitazone (PIO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (PIO; 15 mg for 6 weeks, then 30 mg daily)
Study: 22431401
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation and emotion skills training (CREST) plus treatment as usual
Study: 17699008
Drug: HPV-16/18 L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 L1 protein viruslike particle AS04 candidate vaccine (n = 1088)